Trial Profile
Clinical Application of Intravenous New Castle Disease Virus - HUJ Oncolytic Virus in the Treatment of Advanced Glioblastoma Multiforme, Soft and Bone Sarcomas and Neuroblastoma Patients, Resistant to Conventional Anti- Cancer Modalities
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 16 Jun 2015
Price :
$35
*
At a glance
- Drugs NDV HUJ (Primary)
- Indications Glioblastoma; Neuroblastoma; Osteosarcoma; Soft tissue sarcoma
- Focus Therapeutic Use
- 10 Jun 2015 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
- 18 Aug 2010 New trial record